WO2010044094A3 - A topical composition for the treatment of erectile dysfunction - Google Patents

A topical composition for the treatment of erectile dysfunction Download PDF

Info

Publication number
WO2010044094A3
WO2010044094A3 PCT/IN2009/000484 IN2009000484W WO2010044094A3 WO 2010044094 A3 WO2010044094 A3 WO 2010044094A3 IN 2009000484 W IN2009000484 W IN 2009000484W WO 2010044094 A3 WO2010044094 A3 WO 2010044094A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
topical composition
erectile dysfunction
methyl
pah
Prior art date
Application number
PCT/IN2009/000484
Other languages
French (fr)
Other versions
WO2010044094A2 (en
Inventor
Krishna Radharaman Agarwal
Sanjiv Surajbhan Garg
Original Assignee
Krishna Radharaman Agarwal
Sanjiv Surajbhan Garg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Krishna Radharaman Agarwal, Sanjiv Surajbhan Garg filed Critical Krishna Radharaman Agarwal
Publication of WO2010044094A2 publication Critical patent/WO2010044094A2/en
Publication of WO2010044094A3 publication Critical patent/WO2010044094A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

A topical composition for treatment of erectile dysfunction and pulmonary arterial hypertension (PAH) comprising pharmaceutically effective amount of l-[[3-(6,7- dihydro-l-methyl-7-oxo-3-propyl-IH-pyrazolo[4,3-pyrimidin-5-yl)-4 ethoxyphenyl] sulfonyl] -4-methyl piperazine citrate and desensitizing agent along with pharmaceutically acceptable excipients.
PCT/IN2009/000484 2008-09-03 2009-09-03 A topical composition for the treatment of erectile dysfunction WO2010044094A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1178/MUM/2008 2008-09-03
IN1178MU2008 2008-09-03

Publications (2)

Publication Number Publication Date
WO2010044094A2 WO2010044094A2 (en) 2010-04-22
WO2010044094A3 true WO2010044094A3 (en) 2010-07-01

Family

ID=42106987

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2009/000484 WO2010044094A2 (en) 2008-09-03 2009-09-03 A topical composition for the treatment of erectile dysfunction

Country Status (1)

Country Link
WO (1) WO2010044094A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230022570A1 (en) 2019-12-09 2023-01-26 Futura Medical Developments Limited Topical composition

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10118305A1 (en) * 2001-04-12 2002-10-17 Bayer Ag Composition for intranasal administration of cGMP PDE inhibitor for treatment of erectile dysfunction, also containing local anesthetic to prevent nasal blockage and improve absorption
WO2002102385A1 (en) * 2001-06-14 2002-12-27 Sampad Bhattacharya Compositions comprising cgmppde5 inhibitor for transdermal delivery to the erectile tissue of the penis
US20080206159A1 (en) * 2003-08-04 2008-08-28 Foamix Ltd. Compositions with modulating agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10118305A1 (en) * 2001-04-12 2002-10-17 Bayer Ag Composition for intranasal administration of cGMP PDE inhibitor for treatment of erectile dysfunction, also containing local anesthetic to prevent nasal blockage and improve absorption
WO2002102385A1 (en) * 2001-06-14 2002-12-27 Sampad Bhattacharya Compositions comprising cgmppde5 inhibitor for transdermal delivery to the erectile tissue of the penis
US20080206159A1 (en) * 2003-08-04 2008-08-28 Foamix Ltd. Compositions with modulating agents

Also Published As

Publication number Publication date
WO2010044094A2 (en) 2010-04-22

Similar Documents

Publication Publication Date Title
MY147949A (en) Hydrogenated benzo[c]thiophene derivatives as immunomodulators
TW200708511A (en) Novel thiophene derivatives
TW200718689A (en) 2-Amino-quinazolin-5-ones
TW200738670A (en) Novel thiophene derivatives
MX2009003038A (en) 5-substituted quinazolinone derivatives and compositions comprising and methods of using the same.
WO2006096439A3 (en) Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
WO2007027527A3 (en) Isoindole-imide compounds and compositions comprising and methods of using the same
IL183357A0 (en) Oral medicament for the modified release of at least one active principle, in multimicrocapsule form
WO2006071613A3 (en) Injectable non-aqueous suspension
AP2012006231A0 (en) Capsule formulation of pirfenidone and pharmaceutically acceptable excipients.
WO2010009892A8 (en) Compositions for the treatment of pain and/or inflamation
UA84726C2 (en) Prostaglandin derivatives, process for the preparation thereof, pharmaceutical composition (variants) and method for the treatment of glaucoma and ocular hypertension
WO2006081364A3 (en) Formulations for injection of catecholic butanes, including ndga compounds, into animals
UA90518C2 (en) Pharmaceutical composition in the form of a tablet suitable for dissolution in the buccal cavity, comprising a narcotic active ingredient and amine
WO2006138735A3 (en) Gel compositions for topical administration
WO2007019184A3 (en) Oral suspension of prednisolone acetate
WO2005123135A8 (en) Stabilized compositions comprising a therapeutically active agent, citric acid or a conjugated base and chlorine dioxide
WO2009109654A8 (en) 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, and cx3cr1
WO2009084021A3 (en) Ophthalmic composition comprising a prostaglandin
WO2009035634A3 (en) Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors
IL191758A0 (en) Composition with sustained release of the active ingredient, process for the preparation thereof and use thereof
WO2005101982A3 (en) A stable ophthalmic composition
WO2005105081A3 (en) Therapeutic formulations of desoxyepothilones
WO2008027796A3 (en) Compositions and methods for treating or preventing glaucoma or progression thereof
WO2007126898A3 (en) Use of ladostigil for the treatment of schizophrenia

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09820344

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09820344

Country of ref document: EP

Kind code of ref document: A2